PRODUCT
FDA Criticizes AbbVie for Misleading Ad Featuring Serena Williams Promoting Migraine Drug Ubrelvy
FDA, AbbVie, Serena Williams, Ubrelvy, Migraine Drug, Misleading Advertising
WCLC24 Highlights: ArriVent’s Drug Aims to Address Tagrisso’s Limitations; Boehringer and Bayer Share Data on HER2-Mutated Lung Cancer
WCLC24, ArriVent, Tagrisso, Boehringer, Bayer, HER2-mutated lung cancer, Lung cancer treatment, EGFR-mutated lung cancer
Zealand Pharma’s GLP-1/GLP-2 Receptor Dual Agonist Shows Promising Weight Loss in Phase 1b Trial
Zealand Pharma, GLP-1/GLP-2 receptor dual agonist, dapiglutide, obesity, weight loss, Phase 1b trial
Merck Halts Two Phase 3 Trials of Keytruda for Early-Stage Lung and Skin Cancers
Merck, Keytruda, Phase 3 trials, early-stage lung cancer, skin cancer, KEYNOTE-867, KEYNOTE-630
Johnson & Johnson’s 340B Drug Discount Policy Change Rejected by HHS
Johnson & Johnson, 340B drug discount program, Stelara, Xarelto, HHS, HRSA, drug pricing, hospital payments
Bavarian Nordic Shares Surge on Strong Earnings and Major Mpox Vaccine Order Amid Global Health Emergency
Bavarian Nordic, Mpox Vaccine, Global Health Emergency, WHO, Vaccine Order, Earnings Report
Novartis and Versant Invest $150M in Kidney Biotech Borealis to Replicate Chinook’s Success
Novartis, Versant, Borealis, kidney biotech, $150M investment, Chinook Therapeutics, chronic kidney disease, biotech funding
Bavarian Nordic Ramps Up Mpox Vaccine Production to Combat Global Health Emergency
Bavarian Nordic, Mpox Vaccine, Jynneos, Global Health Emergency, Africa CDC, WHO
FDA Grants Tentative Approval for YUTREPIA, a New Treatment for Pulmonary Arterial Hypertension and Pulmonary Hypertension Associated with Interstitial Lung Disease
YUTREPIA, treprostinil, pulmonary arterial hypertension (PAH), pulmonary hypertension associated with interstitial lung disease (PH-ILD), FDA tentative approval, regulatory exclusivity, United Therapeutics, Tyvaso
Merck Acquires Curon’s Bispecific Antibody in $1.3B Deal; Legend Biotech Evaluates Options Amid Probes; Amgen’s FDA Filing Reveals Missing Adverse Events
Merck, Curon Biopharmaceutical , Bispecific antibody, Legend Biotech, Amgen, FDA filing, Adverse events, China investigations, CAR-T therapy, Carvykti